RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 128 filers reported holding RECURSION PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is 1.27 and the average weighting 1.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $47 | +2.2% | 6,184 | 0.0% | 0.00% | – |
Q2 2023 | $46 | +12.2% | 6,184 | +0.6% | 0.00% | – |
Q1 2023 | $41 | +1950.0% | 6,145 | +1888.7% | 0.00% | – |
Q4 2022 | $2 | -100.0% | 309 | -96.6% | 0.00% | -100.0% |
Q3 2022 | $96,000 | +159.5% | 8,990 | +99.3% | 0.00% | – |
Q2 2022 | $37,000 | -51.9% | 4,510 | 0.0% | 0.00% | -100.0% |
Q4 2021 | $77,000 | +7600.0% | 4,510 | +14933.3% | 0.00% | – |
Q2 2021 | $1,000 | 0.0% | 30 | 0.0% | 0.00% | – |
Q1 2021 | $1,000 | 0.0% | 30 | 0.0% | 0.00% | – |
Q4 2020 | $1,000 | 0.0% | 30 | 0.0% | 0.00% | – |
Q3 2020 | $1,000 | 0.0% | 30 | 0.0% | 0.00% | – |
Q2 2020 | $1,000 | 0.0% | 30 | 0.0% | 0.00% | – |
Q1 2020 | $1,000 | 0.0% | 30 | 0.0% | 0.00% | – |
Q4 2019 | $1,000 | 0.0% | 30 | 0.0% | 0.00% | – |
Q3 2019 | $1,000 | 0.0% | 30 | 0.0% | 0.00% | – |
Q2 2019 | $1,000 | 0.0% | 30 | 0.0% | 0.00% | – |
Q1 2019 | $1,000 | – | 30 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kinnevik AB (publ) | 10,405,668 | $77,730,340 | 100.00% |
Data Collective IV GP, LLC | 5,941,120 | $44,380,166 | 32.86% |
MV Management XI, L.L.C. | 1,971,908 | $14,730,153 | 25.77% |
MIC Capital Management UK LLP | 8,451,758 | $63,134,635 | 12.84% |
Yong Rong (HK) Asset Management Ltd | 1,174,200 | $8,772 | 3.85% |
ArchPoint Investors | 1,114,626 | $8,326,256 | 3.22% |
PLATINUM INVESTMENT MANAGEMENT LTD | 2,711,148 | $20,252,276 | 0.70% |
HARVARD MANAGEMENT CO INC | 882,129 | $6,590 | 0.65% |
Diametric Capital, LP | 119,906 | $895,698 | 0.40% |
Lingotto Investment Management LLP | 775,077 | $5,789,825 | 0.37% |